In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 121 to 130 of 294

TitleTypeExpected publication date
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [review of TA658] [ID4067]Technology appraisal guidanceTBC
Ixazomib citrate for maintenance treatment of untreated multiple myeloma in people who cannot have autologous stem cell transplant [ID2706]Technology appraisal guidanceTBC
Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687]Technology appraisal guidanceTBC
Larotrectinib for treating NTRK fusion-positive advanced solid tumours (MA review of TA630) [ID6292]Technology appraisal guidance
Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043]Technology appraisal guidanceTBC
Lenacapavir for preventing HIV-1 in people aged 16 years or older [ID6495]Technology appraisal guidanceTBC
Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy caused by the G11778A ND4 mitochondrial mutation [ID1410]Technology appraisal guidanceTBC
Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117]Technology appraisal guidanceTBC
Leriglitazone for treating cerebral adrenoleukodystrophy in boys and men 2 years and over [ID3903]Technology appraisal guidanceTBC
Leukocyte interleukin in combination for neoadjuvant treatment of resectable locally advanced squamous cell head and neck cancer [ID6390]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All